**Revlimid Sales to Propel Growth for US Pharma Companies in Q4 FY25**
Higher sales of Revlimid are expected to significantly boost growth for US-focused pharmaceutical companies, including Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories Ltd, and Sun Pharmaceutical Industries Ltd, in the fourth quarter of FY25 and the initial quarters of the upcoming fiscal year.
Analysts predict that these companies will report robust revenue growth of 11-13% in Q4 FY25, driven by strong demand for niche US generic drugs, consistent domestic performance during a typically weak quarter, and increased sales of the blockbuster cancer drug Revlimid before its distribution exclusivity expires next year. However, uncertainties surrounding US tariffs and the conclusion of the limited competition period for generic Revlimid are anticipated to create challenges in 2026.
Kotak Institutional Equities analysts noted that they expect a solid performance in Q4 FY25, supported by stable pricing in the US generics market and positive trends across various other markets, despite sluggish domestic growth in January and February. They forecast year-on-year sales growth of approximately 11% and EBITDA growth of around 17%. Similarly, JM Financial estimates a top-line growth of 10-11%, highlighting that the fourth quarter tends to be softer for some pharma companies with exposure to the Indian market, particularly in the acute segment. However, companies with strong US market presence are likely to perform well during this period.
Several companies, including Dr. Reddy’s, Cipla, Sun Pharma, Zydus Lifesciences, Natco Pharma, and Aurobindo Pharma, have capitalized on the generic versions of Revlimid, a blood cancer drug valued at $8 billion, which has been distributed in limited quantities in the US since March 2022. These companies are set to lose exclusivity on the drug’s distribution in January 2026. Analysts expect Revlimid to be a key driver of growth in Q4 FY25 and beyond.
Despite the anticipated increase in sales, challenges such as price erosion and quarterly volatility are expected. Nomura analysts have indicated that while revenues from generic Revlimid are likely to rise, there may be some price erosion as companies aim to sell their allocated volumes before September 2025.
In conclusion, the upcoming quarters look promising for US-focused pharmaceutical companies, primarily due to the anticipated surge in Revlimid sales, although they must navigate potential pricing pressures and market uncertainties.
**FAQ**
**What is Revlimid and why is it significant for pharmaceutical companies?**
Revlimid is a blockbuster cancer drug used primarily for treating blood cancers. Its significance lies in its substantial market value and the revenue opportunities it presents for pharmaceutical companies, especially as they prepare for the end of distribution exclusivity in 2026.
